A range of available and emerging therapeutic agents across the continuum of prostate cancer offer new options for healthcare providers and their patients. This commentary offers an overview of current treatment strategies and best approaches in diagnosis, treatment, and adverse event management to provide optimal outcomes for patients with prostate cancer.
Oncology NPs, PAs, and nurses
This activity is supported by educational grants from Astellas and Bayer HealthCare Pharmaceuticals Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421GUBC-CTP